| |
Sponsored by:
Who Should Attend:
Biotech and Pharmaceutical Executives
I. Novel Clinical Trials Designs to Speed Approval
Daniel D. Von Hoff, M.D., F.A.C.P., Director, Translational Drug
Development Division, Program Head, Pancreas Cancer Research Programs
and Executive Vice President, TGen; former president, American
Association for Cancer Research
II. Angiogenesis Inhibitors
Judah Folkman, M.D., Professor of Pediatric Surgery and Professor
of Cell Biology, Harvard Medical School; Director, Vascular Biology
Program, Children's Hospital Boston
III. Targeted Therapies
Susan Hellmann, M.D., M.P.H., Executive Vice President and Chief
Medical Officer, Genentech
IV. The Path to FDA Approval and Commercialization
Richard Love, Chief Operating Officer, Translational Genomics
Research Institute
|
